Renishaw neuromate® frameless Gen II cleared by the FDA

7 May 2014

Renishaw is pleased to announce that the U.S. Food and Drug administration (FDA) has issued clearance to market the neuromate® frameless Gen II stereotactic robotic system.

Dr. Abed Hammoud, CEO of Renishaw Mayfield SA said, “We are excited to launch our newest generation neuromate® robotic system in the US, which is the largest global market for medical devices. Our clinical solutions and technical support teams are looking forward to working with some of the leading centres in the US and establishing robotics in the Neuro operating room.”

For further information on Renishaw neurological products, visit www.renishaw.com/neurological.

All images and text copyright Renishaw

Register for news updates

Register for regular news updates from Renishaw